Tumor Symposium

Tumor
Section
Satellite Symposium
Low-grade Gliomas:
Management Strategies Innovations
SAN DIEGO, CALIFORNIA
SEPTEMBER 23-24, 2016
SAN DIEGO CONVENTION CENTER
JOINTLY PROVIDED BY THE CONGRESS OF NEUROLOGICAL
SURGEONS AND THE AANS/CNS JOINT TUMOR SECTION

2 TUMOR SECTION SATELLITE SYMPOSIUM
Experience
our latest
neurotechnology
innovations
Visit us during the Tumor Section and the
Congress of Neurosurgeons Annual Meeting
strykerneurotechnology.com/cns

TUMOR SECTION SATELLITE SYMPOSIUM 1
Dear Colleague,
Welcome to the 2016 Tumor Section Satellite Symposium in San
Diego! Over the next two days, we will explore our meeting theme,
Low-grade Gliomas: Management Strategies Innovations,
and examine advancements in the treatment of adult and pediatric
brain tumors. With your participation, we look forward to
engaging scientific sessions covering recent clinical trials, tumor
guidelines, and next-generation techniques in surgical, medical,
and radiation therapies.
We are pleased to welcome keynote speakers Mitchel Berger,
Hugues Duffau, and James Rutka as well as many distinguished
brain tumor experts slated to present during our four General
Sessions. We are also grateful to our sponsors and exhibitors, whose
support helped make this meeting possible. Please remember
to connect with these industry partners for lunch and afternoon
breaks in the exhibit hall.
Residents, fellows, and junior attendings are invited to
participate in small-group breakfast breakout sessions on Saturday
morning. These are outstanding opportunities to meet senior brain
tumor surgeons and learn how to set up a practice, start a lab, or
seek out an academic position.
We hope to see you at the 31st Anniversary Gala Reception
Friday evening at the historic US Grant Hotel. Join us in honoring
the recipients of this year’s Wilson Award, Distinguished Service
Award, and Parsa Mentoring Award.
Finally, we are proud to host our meeting for the first time in
conjunction with the Congress of Neurological Surgeons Annual
Meeting. If you plan to stay on for more great science this week,
don’t forget to connect with us again at the Tumor Section sessions
at the CNS Annual Meeting.
Thank you for being a part of this meeting as together we move
the treatment and care of brain tumor patients forward.
Sincerely,
TABLE OF CONTENTS
Learning Objectives 2
CME Information 2
Program Schedule 3-15
Floor Plans 16-19
Exhibitors 18
General Information 21-22
Disclosures 23-24
SECTION CHAIR
Steven N. Kalkanis
MEETING CHAIR
Chetan Bettegowda
MEETING CHAIR
Brian V. Nahed

Symposium Description
This symposium will provide an up-to-date overview of the
management of low-grade tumors in adult and pediatric patients,
emphasizing cutting-edge and next-generation techniques
in medical, surgical, and radiation therapies. It will identify
the molecular and genetic changes and efforts to target these
mutations in state-of-the-art therapy.
Learning Objectives
Upon completion of this symposium participants should be able to:
• Develop treatment strategies for patients with low-grade glioma
at diagnosis and recurrence
• Discuss advancements in understanding of low-grade glioma
biology and relevance to outcome
• Discuss emerging surgical, medical, and radiation techniques to
achieve the best outcome
CME Information
ACCREDITATION
This activity has been planned and
implemented in accordance with the
accreditation requirements and policies of
the Accreditation Council of Continuing
Medical Education (ACCME) through the
joint providership of the Congress of Neurological Surgeons and
the Tumor Section. The CNS is accredited by the ACCME to
provide continuing medical education for physicians.
AMA CREDIT DESIGNATION STATEMENT
The CNS designates this live activity for a maximum of
12.75 AMA PRA Category 1 CreditsTM
. Physicians should only
claim credit commensurate with the extent of their participation
in the activity.
CLAIMING CME CREDIT
CME credits can be claimed through the online CME system at
www.cns.org. The CME tracking system allows you to create and
print a CME certificate immediately following the Tumor Section
Satellite Symposium while you are still in San Diego, or from the
convenience of your home or office. Log in using your last name
and the email address with which you registered. You will need
to enter the number of hours you are claiming for each session
you attended. Physicians should only claim credit for the learning
activities in which they actively participated. Upon completion of
this process, your CME certificate will be sent to you via email at
the email address you provided at registration.
MID-LEVEL PRACTITIONERS
Attendees will receive a certificate of completion. Please contact
your individual membership association and certification board to
determine the requirements for accepting credits.

Program Schedule
Friday, September 23, 2016
8:00 am–5:00 pm
Registration Ballroom 6 Lobby, Upper Level
General Session 1 Room 6B, Upper Level
Biology and Management of LGG
10:00–10:10 am
Opening Remarks
Chetan Bettegowda, Steven N. Kalkanis, and
Brian Nahed
10:10–10:25 am
Biology of Low-grade Gliomas
Robert Jenkins
10:25–10:40 am
Diagnosis: Medical Management/Chemotherapy
and Timing
Susan Chang
KEYNOTE SPEAKER 1
10:40–11:10 am
Maximizing Resection for Survival/When to
Operate
Mitchel S. Berger, MD, chair of
neurological surgery at University of
California San Francisco, is a nationally
recognized expert in treating brain and
spinal cord tumors and tumor-related
epilepsy in adults and children. He also is a
specialist in brain mapping techniques, used
to identify areas of motor, sensory and language function during
surgery, and an expert in the use of the Gamma Knife for tumor
treatment. He is co-director of the Adult Brain Tumor Surgery
Program, director of the Brain Tumor Research Center, and
director of the Center for Neurological Injury and Repair.
11:10–11:25 am
Radiation Therapy
Jennifer Yu

11:25–11:40 am
Recurrence and Progression to High-grade
Houtan Noushmehr
11:40–11:55 am
Clinical Trials, Targeted Therapies, Mechanisms
Steven Yip
11:55 am–12:10 pm
Joint Section on Tumors Guidelines
Jeffrey J. Olson
12:10–1:10 pm
Lunch with Exhibitors in the Exhibit Hall
Room 6A, Upper Level
12:10–1:10 pm
Sponsored Lunch Seminar Room 6B, Upper Level
Controversies in Fluorescence Guided
Surgery (FGS) of Gliomas: Fluorescein
vs. 5-ALA
Surgical Techniques and
Adjuvant Therapy
KEYNOTE SPEAKER 2
1:15–1:45 pm
Mapping Intraoperatively to Maximize Resection
Hugues Duffau, MD, PhD, is professor
and head of the department of neurosurgery at
the University Hospital Centre of Montpellier,
France. A leading expert on low-grade glioma
surgery, Dr. Duffau pioneered surgery of
still-conscious patients with brain tumors,
resulting in a new model of the brain based on
plasticity and connectivity. He has authored more than 225
publications and four books, including Brain Mapping: From Neural
Basis of Cognition to Surgical Applications, published in 2011.
1:45–1:55 pm
Pre-operative Imaging/fMRI
1:55–2:05 pm
Intraoperative Imaging
Christian Rainer Wertz
2:05–2:15 pm
Intraoperative Ultrasound
Francesco DiMeco
Program Schedule

2:15–2:25 pm
Intraoperative 5-ALA
Walter Stummer
2:25–2:35 pm
Fluroscent Alkylphosphocholine for Intraoperative
Detection
John Kuo
2:35–2:45 pm
Intraoperative Mass Spectroscopy
Kevin Petrecca
2:45-2:55 pm
Raman Spectroscopy
Steven N. Kalkanis
2:55–3:05 pm
Intraoperative Viral Vectors
Manish Aghi
3:05–3:30 pm
Break with Exhibitors Room 6A, Upper Level
Sponsored by:
3:30–5:00 pm
Abstract Presentations 1: Selected Oral Abstract
Presentations and Discussion Room 6B, Upper Level
Moderators: Gordon Li and Pamela Jones
3:30–3:35 pm
Supratotal Resection in Low-grade Gliomas:
Feasibility and Clinical Impact
Marco Rossi, Marco Riva, Federico Pessina,
Alessandra Casarotti, Lorenzo Bello
3:35–3:40 pm
The Benefit of Gross Total Resection Across
Glioma Subtypes: A Comparison of Grade II/III/
IV Gliomas in the Surveillance, Epidemiology,
and End Results (SEER) Database
Brian R. Hirshman, Ali A. Alattar, Alexander J.
Schupper, Jennifer Padwal, Michael G. Brandel,
Xuezhi Dong, Bob S. Carter, Clark C. Chen
3:40–3:45 pm
The Value of Extent of Resection for Genetically
“Favorable” and “Unfavorable” High-grade
Gliomas: Analysis of the TCGA Data
Shawn L. Hervey-Jumper, David Altshuler, Karam
Paul Asmaro, Lisa Scarpace, Tom Mikkelsen,
Steven N. Kalkanis
3:45–3:50 pm
Surgical Outcomes and Complications
after Reoperation for Recurrent Skull Base
Meningiomas
Stephen T. Magill
Program Schedule

3:50–3:55 pm
Atypical and Anaplastic Meningioma (AAM):
Outcomes in a Population-based Study
Tomas Garzon-Muvdi, Wuyang Yang, Michael Lim,
Henry Brem, Judy Huang
3:55–4:00 pm
Thermal Injury to Corticospinal Tract Predicts
Post-operative Motor Deficits Following Laser
Interstitial Thermal Therapy
Mayur Sharma, Ghaith Habboub, Danilo Silva,
Gene H. Barnett, Alireza M Mohammadi
4:00–4:05 pm
Portable Intraoperative Computed Tomography
Scan in Image-guided Surgery for Brain High-
grade Gliomas: Analysis of Technical Feasibility
and Impact on Extent of Tumor Resection
Giuseppe Barbagallo, Stefano Palmucci,
Massimiliano Visocchi, Sabrina Paratore, Giancarlo
Attinà, Giuseppe Sortino, Vincenzo Albanese,
Francesco Certo
4:05–4:10 pm
Surgical Resection for Intracranial Malignant
Teratomas: A Population-based Study
Wuyang Yang, Xiaoming Rong, Tomas Garzon-
Muvdi, Jose Luis Porras, Xuan Hui, Judy Huang
4:10–4:15 pm
Sources of Variation Influencing Concordance
Between Functional MRI and Direct Cortical
Stimulation in Brain Tumor Surgery
Melanie Morrison, Fred Tam, Marco Garavaglia,
Gregory Hare, Michael Cusimano, Tom Schweizer,
Simon Graham, Sunit Das
4:15–4:20 pm
Sodium Fluorescein Facilitates Guided Sampling
of Diagnostic Tumor Tissue in Non-enhancing
Gliomas
Stephen G. Bowden, Brian John Andrew Gill,
Randy D’Amico, Timothy H Ung, Peter Chang,
Justin A. Neira, Jorge Samanamud, Sameer A.
Sheth, Guy M. McKhann, Michael B. Sisti, Peter D.
Canoll, Jeffrey N. Bruce
4:20–4:25 pm
Subventricular Zone Contact, but not
Subgranular Zone, Corpus Callosal, nor Cortical
Contact, Predicts Survival in Surgically Treated
Glioblastomas
Akshitkumar Mistry, Michael C. Dewan, Gabrielle
A. White-Dzuro, Philip Ryan Brinson, Kyle D.
Weaver, Reid C. Thompson, Rebecca Ihrie,
Lola Blackwell Chambless
Program Schedule

4:25–4:30 pm
Incidence of Leptomeningeal Disease
Following Ventricular Entry During Resection of
Supratentorial Grade IV Glioma
Ben Allen Strickland, Dima Suki, Rory R. Mayer,
J. Matthew Debnam, Ian E. McCutcheon, Raymond
E. Sawaya, Jeffrey S. Weinberg
4:30–4:35 pm
Initial Experience with an Image-guided
Robotically Positioned Optical Platform for Skull
Base Surgery
Amin B. Kassam, Srikant S. Chakravarthi, Juanita
Celix, Sammy Khalili, Martin Corsten, Sarika Walia,
Jonathan Jennings, Melanie Fukui, Richard A.
Rovin
4:35–4:40 pm
Cranial Chordoma: A New Classification System
and Validation
Harley Brito da Silva, David Straus, Manuel
Ferreira Jr., Robert C. Rostomily, Jason Barber,
Laligam N. Sekhar
4:40–4:45 pm
Diagnostic Accuracy of PET, SPECT, and
Arterial Spin-Labeling in Differentiating Tumor
Recurrence from Necrosis in Cerebral Metastasis
after Stereotactic Radiosurgery
Clark C. Chen, Grace Y. Lai, David Hackney,
Peter C. Warnke, Eric T. Wong, Bob S. Carter
4:45–4:50 pm
Cochlear Radiation Dose Is Associated with
Decreased Hearing Preservation for Vestibular
Schwannoma Patients Treated with Radiosurgery
Lawrance K. Chung, Nolan Ung, Winward Choy,
Carlito Lagman, Panayiotis Emmanuel Pelargos,
Brittany Voth, Alessandra A. Gorgulho, Stephen
Tenn, Nader Pouratian, Tania B. Kaprealian,
Michael T. Selch, Antonio DeSalles, Quinton
Gopen, Isaac Yang
4:50–4:55 pm
A Morphometric Survey of the Parasellar Region
of over 2700 Skulls with Particular Emphasis on
the Middle Clinoid Process
Akshay Sharma, Gabrielle E. Rieth, Joseph E.
Tanenbaum, Sunil V. Manjila, Buelent Yapicilar
4:55–5:00 pm
Proposing a Validated Clinical App for Predicting
Unfavorable Outcomes in Patients Undergoing
Craniotomy for Excision of Acoustic Neuroma
Piyush Kalakoti, Jerry McLarty, Kanika Sharma,
Maura Cosetti, Anil Nanda
Program Schedule

7:00–10:00 pm
31st Anniversary Gala Reception at the historic
US Grant Hotel
Presentation of the Wilson Award, Distinguished
Service Award, and Mentoring Award
Complimentary shuttle service will depart from the
Marriott Marquis San Diego Marina Hotel’s lower front
drive at 6:45 pm. Shuttles will return to the Marriott
upon the conclusion of the event.
Saturday, September 24, 2016
7:00 am–12:00 pm
Registration Ballroom 6 Lobby, Upper Level
7:00 am–5:00 pm
Abstract Digital Poster Viewing in Exhibit Hall
Breakfast Breakouts for Residents,
Fellows, Medical Students, and
Young Attendings
8:00–9:00 am
Developing an Independent Research Program/
Lab as a Neurosurgeon Room 10, Upper Level
John Sampson and Manish Aghi
8:00–9:00 am
Neurosurgeons as Clinical Trial
Investigators Room 11A, Upper Level
Fred Barker, Michael Lim, and Michael Vogelbaum
8:00–9:00 am
Finding a Neurosurgery Position as a Brain
Tumor Surgeon Room 11B, Upper Level
Bob Carter and Ricardo Komotar
Program Schedule

9:10–10:20 am
Moderators: Graeme Woodworth and Nduka
Amankulor
9:10–9:15 am
Re-visiting Racial Disparity in Outcomes
Following Craniotomy for Resection of Adult
Intracranial Tumors
Piyush Kalakoti, Kanika Sharma, Christina
Notarianni, Anil Nanda
9:15–9:20 am
Racial Disparity in Short-term Outcomes and
Hospital Costs in Pediatric Patients Undergoing
Craniotomy for Resection of Brain Tumors:
Insights from Kids’ Inpatient Database (KID)
Piyush Kalakoti, Kanika Sharma, Anil Nanda,
Christina Notarianni
9:20–9:25 am
Early Discharge after Craniotomy Is Safe and
Associated with Decreased 30-day Readmissions
and Decreased Risk of DVT/PE
Angela Richardson, Jagteshwar Sandhu, David
McCarthy, Roxanne Mayrand, Christine Guerrero,
Ricardo Jorge Komotar, Michael E. Ivan
9:25–9:30 am
Differences in Patterns of Care and Prognosis
in Elderly versus Non-elderly Patients with
Glioblastoma
Patrick Michael Flanigan, Arman Jahangiri, Ruby
Kuang, Albert Truong, Sarah Choi, Alvin Chou,
Annette Molinaro, Michael William McDermott,
Mitchel S. Berger, Manish Kumar Aghi
9:30-9:35 am
Bone Marrow Response as a Potential Biomarker
of Outcomes in Glioblastoma Patients
Eugene John Vaios, Brian V. Nahed, Alona
Muzikansky, Amir Fathi, Jorg Dietrich
9:35–9:40 am
Dosimetric Thresholds Predicting High Risk of
Radionecrosis in Gamma Knife Radiosurgery
for Cerebral Metastases
Steven L. Gogela, Yair M. Gozal, John Thaman,
Bryan Matthew Krueger, Ronald E. Warnick
Program Schedule

9:40–945 am
Cochlear Function as a Novel Predictor of
Hearing Preservation in Vestibular Schwannomas
after Stereotactic Radiosurgery
Amparo M. Wolf, Svetlana Kvint, Aram Modrek,
Carolina Gesteira Benjamin, John G. Golfinos,
Joshua Silverman, Douglas Kondziolka
9:45–9:50 am
Hypofractionated Radiosurgery for the
Treatment of Large Brain Metastases and Post-
resection Cavities
Yair M. Gozal, Timothy Struve, Steven L. Gogela,
Eric Wolf, McGill Brian, Michael Lamba, Luke E.
Pater, John C. Breneman, Ronald E. Warnick
9:50–9:55 am
VTE in Patients Undergoing Craniotomy for Brain
Tumors: A NSQIP Analysis
David J. Cote, Heloise H. Dubois, Aditya Vishwas
Karhade, Timothy R. Smith
9:55–10:00 am
Extra-pseudocapsular Dissection Technique
for Growth Hormone (GH)-Secreting Pituitary
Adenomas by Endoscopic Endonasal
Transsphenoidal Approach
Xiao-jie Lu, Qing Wang, Bing Li, Jiang-an Li,
Jing Wang
10:00–10:05 am
Infectious Complications after Craniotomy for
Tumor: A National Surgical Quality Improvement
Program Analysis
Hormuzdiyar H. Dasenbrock, Sandra C. Yan,
Timothy R. Smith, Elizabeth Claus, William B.
Gormley, Ian F. Dunn
10:05–10:10 am
Development of Persistent Mucoid Spinal Cord
Mass in a Patient Following Olfactory Mucosal
Stem Cell Transplantation to Treat Spinal Cord
Injury
Navin Sabharwal, Elizabeth Emily Bennett,
Abdi S. Ghodsi, Glen Stevens, Andrew Torre Healy,
Edward C. Benzel
10:10–10:20 am
Questions and Answers
10:20–10:40 pm
Sponsored by:
Program Schedule

General Session 3: Room 6B, Upper Level
Pediatric Low-grade Tumors
10:40–10:50 am
Opening Remarks
Chetan Bettegowda and Brian Nahed
10:50–11:10 am
Medical Management of Pediatric Low-grade Tumors
Nathan Robison
11:10–11:30 am
Radiation of Pediatric Low-grade Tumors
Mary McAleer
11:30 am–12:15 pm
Moderators: Peter Fecci and Kaisorn Chaichana
11:30–11:35 am
Tumorigenic Alterations by Mutant IDH1 in Early
Gliomagenesis
Aram Modrek, Themasap Khan, Danielle Golub,
Michael Kader, Guoan Zhang, Jingjing Deng, Chris
Bowman, Nermin Sumru Bayin, Joshua Frenster,
Tenzin Lhakhang, Adriana Heguy, John Dankert,
Aristotelis Tsirigos, Matija Snuderl, Thomas
Neubert, Dimitris G. Placantonakis
11:35–11:40 am
Integrated Prognostication of Molecular
Oligodendroglioma in the Cancer Genome Atlas
Sameer H. Halani, Michael Nalisnik, Chad Holder,
Jun Kong, Jose Enrique Velazquez Vega, Jeffrey J.
Olson, Lee Cooper, Daniel J. Brat
11:40–11:45 am
Epigenetic Regulation of Mesenchymal
Transition by CBX6 in GBMs
Yujun Wang, Gang Li, Mike Yue Chen
11:45–11:50 am
High Dimensional Analysis of Glioblastoma
Multiforme by Mass Cytometry
Ahmed M. Mohyeldin, Yannick Simmone,
Evan Newell, Ichiro Nakano
11:50–11:55 am
A Cerebrospinal Fluid microRNA Signature for
Glioblastoma Detection
Johnny Akers, Valya Ramakrishnan, Ying Mao,
Wei Hua, Bob S. Carter, Clark C. Chen
11:55 am–12:00 pm
Three Dimensional Bioprinting of the Human
Gliovascular Unit
Robert Thomas Wicks, Young-Joon Seol,
Goodwell Nzou, Elizabeth E. Wicks, Sang Jin Lee,
Sean V. Murphy, James J. Yoo, Anthony Atala
Program Schedule

12:00–12:05 pm
Confocal Laser Endomicroscopic (CLE)
Characterization of the Normal Brain
Cleopatra Charalampaki, Alhadi Igressa
12:05–12:10 pm
Putting the Brakes on Brachyury: Identifying and
Targeting a Conserved Transcriptional Network
that Drives Primary and Metastatic Brain Tumor
Initiation and Propagation
Sagar R. Shah MS, Justin M David, Nathaniel
Tippens, Ahmed Mohyeldin, Juan Carlos Martinez-
Gutierrez, Sara Ganaha, Kristen Kozielski, Jordan
Green, Andre Levchenko, Claudia Palena, Alfredo
Quinones-Hinojosa
12:10–12:15 pm
ZR30, an in vitro Synthesized EFEMP1-derived
Tumor Suppressor Protein Targets MMP2, EGFR,
NOTCH1, and AKT Signaling from Extracellular
Compartment of Different Glioma Cell
Subpopulations of Intracranial Xenografts
Yi-Hong Zhou, You-Xin Zhou, Yanyan Li MSc, Yuan
Hu, Chuaniin Liu, Qingyue BS Wang, Xiaoxiao Han,
Yong Han, Xue-Shun Xie, Xiong-Hui Chen,
Eric R. Siegel, Kambiz Afrasiabi, Mark E. Linskey
12:15–1:15 pm
Lunch with Exhibitors in the Room 6A, Upper Level
Exhibit Hall
KEYNOTE SPEAKER 3
1:15–1:45 pm
Surgery for Pediatric Low-grade Tumors
James Rutka, MD, PhD, is RS McLaughlin
professor and chair of the department of
surgery at the University of Toronto, and also
serves on the surgical staff at the Hospital for
Sick Children in the Division of Pediatric
Neurosurgery. Editor-in-chief of the Journal of
Neurosurgery, Dr. Rutka’s primary research and
clinical interests relate to the science and surgery of human brain
tumors. His laboratory interests lie in the molecular biology of human
brain tumors—specifically in the determination of the mechanisms by
which brain tumors grow and invade. His recent clinical interests have
centered on the surgical treatment of epilepsy in children. He has over
400 peer-reviewed publications.
Program Schedule

Outcomes and the Future
1:45–2:05 pm
Molecular Classification and Outcomes of
Low-grade Glioma
Adam Resnick
2:05–2:25 pm
Upcoming Targets in Low-grade Glioma
Andrew Chi
2:25–2:45 pm
Emerging Technologies Monitoring for
Recurrence/Progression
Chetan Bettegowda, Clark Chen, and Brian Nahed
2:45–3:00 pm
Parsa Mentoring Award
Steven N. Kalkanis
3:00–3:35 pm
3:35–5:00 pm
Moderators: Sunit Das and Chris Farrell
3:35–3:40 pm
Immune Checkpoint Blockade as a Potential
Therapeutic Target: Surveying CNS Malignancies
Sarah Tamara Garber, Yuuri Hashimoto, Shiao-
Pei Weathers, Joanne Xiu, Zoran Gatalica, Roel
Verhaak, Shouhao Zhou, Gregory N. Fuller,
Mustafa Khasraw, John Degroot, Sandeep Reddy,
David Spetzler, Amy B. Heimberger
3:40–3:45 pm
Peripheral Lymphocytic Immune Checkpoint
Landscape in Primary and Recurrent Glioblastoma
Leonel Ampie, Winward Choy, Jonathan
Balquiedra Lamano, Joseph D. DiDomenico, Kartik
Kesavabhotla, Orin Bloch
3:45–3:50 pm
Treatment with Hypomethylating Agent
Decitabine Can Reverse Immune Escape by
Isocitrate Dehydrogenase Mutant Gliomas
Xiaoran Zhang MS, Aparna Rao, Christopher P.
Deibert, Wajin Jason Kim, Alexander Pomerantz,
Nduka M. Amankulor
3:50–3:55 pm
CCL21 Vault Nanoparticle as an
Immunotherapeutic for Glioblastoma
Panayiotis Emmanuel Pelargos, Brittany Voth,
Nikhilesh Bhatt, Carlito Lagman, Nolan Ung,
Winward Choy, Isaac Yang
Program Schedule

3:55–4:00 pm
Sulforaphane Inhibits the Formation of Glioma
Induced Myeloid Derived Suppressor Cells and
Reduces Myeloid PDL1 Expression
Ravi Kumar, Ian F. Parney
4:00-4:05 pm
Craniotomy for Intracranial Melanoma
Metastases Offers a Bridge Towards Enhancing
Efficacy of Checkpoint Inhibitor Therapy
Christopher Alvarez-Breckenridge, Corey Gill, Mia
Bertalan, Daniel P. Cahill, Ryan Sullivan, Priscilla
Brastianos
4:05–4:10 pm
Validation of the Programmed Death-Ligand 1
Antibody Clone 28-8 for Immunohistochemistry
in Brain Tumor Patients
Arnold Obungu, Saman Sizdahkhani, Graham
Lobel, Nancy A. Edwards, Edjah K. Nduom
4:10–4:15 pm
Synergistic Anti-tumor Effect with Indoleamine
2,3-dioxygenase Inhibition and Temozolomide
in a Murine Glioma Model
Hiroyuki Kinouchi, Mitsuto Hanihara, Tomoyuki
Kawataki
4:15–4:20 pm
A Potential New Adjunct to Temozolomide
Therapy in Glioblastoma
Gary R. Simonds, Cara Rogers
4:20–4:25 pm
Combined Multimodality Treatment with
Hypoxia-activated Prodrug TH-302 and XRT
Results in Enhanced Antitumor Efficacy in
Preclinical Malignant Meningioma Mouse Model
Asif Maknojia, Vaibhav Patel, Michael Garcia, Dave
Cavazos, Courtney Bosse, Aleksandra Gruslova,
Niko Papanikolaou, Andrew Brenner, John Robert
Floyd
4:25–4:30 pm
Preclinical Study and Translational Application
of Concurrent Radiotherapy and Valproic Acid
for Intracranial Hemangioblastomas in Sporadic
Hemangioblastomatosis
Gautam U. Mehta, Saman Sizdahkhani,
Charlton Smith, Christina Hayes, DeeDee Smart,
Prashant Chittiboina
Program Schedule

4:30–4:35 pm
Phosphatase 2A Inhibitor, LB100, Sensitizes
Malignant Meningioma Cells to Radiation by
Autophagy Inhibition
Sze Chun Winson Ho, Saman Sizdahkhani,
Anita Tandle, Dragan Maric, Deric M. Park,
Zhengping Zhuang, John D. Heiss
4:35–4:40 pm
Modulation of Radiation Induced Cell Death
in Glioma via Cadherin-mediated Tumor
Microenvironment Alteration
Christopher Paul Cifarelli
4:40–4:45 pm
Engineering Primary Patient-derived Adipose
Mesenchymal Stem Cells (hMSCs) with
Nanoparticles: An Autologous “Trojan Horse” for
the Intraoperative Treatment of Brain Cancer
Rawan Alkharboosh, Kristen Kozielski, Jordan
Green, Alfredo Quinones-Hinojosa
4:45–4:50 pm
Self-assembling Camptothecin Hydrogel:
A Local Treatment for Brain Tumors
Montserrat Anilu Lara-Velazquez, Paula
Schiapparelli, Ran Lin, Pengcheng Zhang, Hao Su,
Hugo Guerrero Cazares, Honggang Cui, Alfredo
Quinones-Hinojosa
4:50–4:55 pm
Disulfiram Sensitizes Glioblastoma to Abraxane
and Temozolomide Treatment Through Inhibition
of MGMT and Aldehyde Dehydrogenase
George C. Bobustuc, Deborah L. Donohoe,
Richard A. Rovin, Amin B. Kassam, Santhi D.
Konduri
4:55–5:00 pm
Acid Ceramidase is a Novel Drug Target Against
Multiple Pediatric Brain Tumors
Ninh Doan, Wade M. Mueller, Shama Mirza,
Kathleen M. Schmainda, Mona Al-Gizawiy,
Andrew Montoure, Ha Nguyen
Program Schedule

Convention Floor Plan
Convention Center Overview
6A
Tumor Exhi
Ballroom 6 Lobby
Tumor Registration
10, 11A, 11B
Breakfast
Breakouts
Convention Center Upper Level
San Diego Conve
GROUND LEVEL
Registration | Saturday to Wednesday
Exhibit Hall C | Monday to Wednesday | General Scienti
Monday Tuesday | Operative Neurosur
Monday | Clinical Trials Update Sessions
CNS E
(Exhib
CNS HOTEL S
OVERVIEW
UPPER LEVEL MEETING ROOMS/BAL
MEZZANINE LEVEL MEETING ROOMS
GROUND LEVEL EXHIBIT HALLS
UNDERGROUND
PARKING GARAGE 2 LEVELS
SAN DIEGO BAY
FIRST
AVENUE
FRO
NT
STREET
WEST HARBOR DRIVE
GASLAMP QUARTER
98 #CNS2016

6B
Tumor General
Session Abstract
Oral Presentations
ibit Hall
5B
Speaker Ready
Room
ention Center
ific Sessions
rgery Sessions
s
EXHIBIT HALL
bit Halls A B)
REGISTRATION ENTRANCE
from Marriott Marquis
San Diego Marina Hotel
SHUTTLES
LLROOMS/SAILS PAVILION
PARKING
STRUCTURE
FIFTH
AVENUE
SAN DIEGO BAY
CONVENTION WAY

Exhibit Hall Floor Plan
EXHIBITOR BOOTH
Arbor Pharmaceuticals 307, 313
Brainlab 305
BioD, LLC 306
Carl Zeiss 311
Medtronic 309
Monteris Medical 304
Stryker 308
Exhibitors
Ballroom 6-Lobby

Thank you
Corporate Supporters
Silver Supporter
Carl Zeiss
Bronze Supporters
Arbor Pharmaceuticals
Medtronic
Stryker
BioD, LLC
Monteris Medical

PP-GLD-US-0142
Vigilant ObservatIon of GlIadeL
WAfer ImplaNT (VIGILANT)
Registry: A Multicenter,
Observational Registry to
Collect Information on the
Safety and Effectiveness
of Gliadel® Wafer
(Carmustine Implant) Used in
Usual Medical Practice
Sponsored by Arbor Pharmaceuticals, LLC
For more information about
the VIGILANT Registry,
or if you are interested in
participating, please contact
the study team at:
VIGILANT@mapigroup.com
1.855.843.6778 (phone/fax)
ClinicalTrials.gov #NCT02684838
Visit Arbor Medical Affairs
Booth 313 to learn more about

General Information
Americans with Disabilities Act
The Tumor Section wishes to take those steps to ensure that
no individual with a disability is excluded, denied services,
segregated, or otherwise treated differently than other
individuals because of the absence of auxiliary aids or services. If
you require any of the auxiliary aids or services identified in the
Americans with Disabilities Act in order to attend any program,
please send your requirements directly to the CNS Meetings
Department at meetings@cns.org or by calling 847-240-2500.
Attire
Professional attire is appropriate for the meeting and in the
Exhibit Hall. Professional /dressy attire is appropriate for the
Friday, September 23, Gala Reception and Dinner.
Meeting App
Conveniently manage your schedule, browse
program content, and keep up with what’s
going on. Download the free EventPilot app
from the Apple or Google Play store. Log in
with the event code:
TUMOR16
WiFi Service
For your convenience, complimentary Wi-Fi
service is provided by the CNS throughout
the San Diego Convention Center wherever
Tumor Section events are being held.
Network Name: cns Conference
Conference Passcode: cns2016

Disclaimer
The material presented at the 2016 Tumor Section Satellite Symposium
has been made available by the Tumor Section for educational
purposes only. The material is not intended to represent the only, nor
necessarily the best, method or procedure appropriate for the medical
situations discussed, but rather is intended to present an approach,
view, statement, or opinion of the faculty which may be helpful to
others who face similar situations.
Neither the content (whether written or oral) of any course,
seminar, or other presentation in the program, nor the use of a specific
product in conjunction therewith, nor the exhibition of any materials
by any parties coincident with the program, should be construed
as indicating endorsement or approval of the views presented, the
products used, or the materials exhibited by the Tumor Section or by
its Committees or Affiliates.
The Tumor Section disclaims any and all liability for injury or
other damages resulting to any individual attending the meeting,
and for all claims which may arise out of the use of the techniques
demonstrated therein by such individuals, whether these claims shall
be asserted by physicians or any other person.
No reproductions of any kind, including audiotapes and
videotape, may be made of the presentations at the Tumor Section
Satellite Symposium. The Tumor Section reserves all of its rights to
such material, and commercial reproduction is specifically prohibited.
Onsite Registration Hours
Friday, September 23
8:00 am–5:00 pm
Saturday, September 24
7:00 am–12:00 pm
Exhibit Hall Hours
12:00 pm–5:00 pm
7:00 am–5:00 pm
Admittance to the Exhibit Hall is by Tumor Section Satellite
Symposium name badge only. Children under the age of 18 are not
allowed in the Exhibit Hall.
Smoking
The San Diego Convention Center and official Tumor Section
Satellite Symposium hotels are non-smoking facilities.
Speaker Ready Room
All speakers and abstract presenters should visit the Speaker
Ready Room (Room 5B) at the San Diego Convention Center a
minimum of 1 hour prior to their presentations.
8:00 am–5:30 pm
7:00 am–4:30 pm

Disclosures
The Congress of Neurological Surgeons controls the content
and production of this CME activity and attempts to assure the
presentation of balanced, objective information. In accordance
with the Standards for Commercial Support established by the
Accreditation Council for Continuing Medical Education, speakers
are asked to disclose any relationship they have with commercial
companies which may be related to the content of their lecture.
Speakers who have disclosed a relationship with commercial
companies whose products may have a relevance to their
presentation are listed below. Faculty who are also considered
Planners are designated by P. Disclosures are current as of
August 16, 2016.
Positional Interest Codes
1 CEO
2 Consultant
3 Director
4 Editorial Board
5 Employee
Gene H. Barnett
Consulting Agreement - Monteris
Medical Company (2)
Edward C. Benzel, MD
Consulting Agreement - Axiomed (2)
Daniel P. Cahill, MD
Consulting Agreement - Merck (2)
Susan Chang, MD
Consulting Agreement - Edge
Therapeutics (2), Neonc (2), Tocagen
(2), Other - Agios (6), Novartis (6),
Quest (6), Roche (6)
Clark C. Chen, MD, PhD
Consulting Agreement – Monteris (2),
MRI Intervention (2), Tocagen (2),
Mike Yue Chen, MD, PhD
Consulting Agreement – Globus (2):
Royalty – Globus Medical (2)
Ownership Interest – Medplate (7);
Grants – Orthofix ((N/A)
John G. Golfinos, MD
Consulting Agreement - Viewray (6)
William B. Gormley, MD
Consulting Agreement - Codman (6)
Amy B. Heimberger, MD
Consulting Agreement - Caris Life
Sciences (2)
Michael E. Ivan, MD, MBS
Consulting Agreement - Medtronic
(2)
Amin B. Kassam, MD
Consulting Agreement – Synaptive
Medical (2)
Ricardo Jorge Komotar, MD
(2)
Gordon Li, MD
(2)
Michael Lim, MD
Consulting Agreement - accuray (2),
bms (2), Izi (2), Stryker (2), Grants -
Accuray (6), Aegenus (6), Altor (6),
Celldex (6), Immunocellular (6)
Jeffrey J. Olson, MD
Grants - Roche (6)
Kevin Petrecca, BSc, MD, PhD
Ownership Interest - ODS Medical (8)
Dimitris G. Placantonakis, MD, PhD
Other – Tocagen, Inc. (2)
Laligam N. Sekhar, MD
Other -Spisurgical (6), Viket Medical,
Inc. (6)
Walter Stummer, MD
Consulting Agreement - Medac (2),
Nxpharmagene (2), Zeiss (2)
Michael A. Vogelbaum, MD, PhD
Honoraria - Neuralstem, Inc. (6),
Pharmicokinesis (6),
Ownership Interest - Infuseon
Therapeutics (7),
Royalty - Infuseon Therapeutics (7)
Buelent Yapicilar, MD
Grants - Stryker (6)
Yi-Hong Zhou, PhD
Ownership Interest – Patent on
protein and Nucleotide Sequences
of ETSP ((8) Nothing to
6 N/A
7 Officer
8 Owner
9 Trustee

Kambiz Afrasiabi, MD
Manish Kumar Aghi, MD, PhD
Johnny Akers
Ali A. Alattar, BS
Vincenzo Albanese
Mona Al-Gizawiy, PhD
Rawan Alkharboosh, MS
David Altshuler, MD
Nduka M. Amankulor, MD
Leonel Ampie, BS
Karam Asmaro, MD
Anthony Atala, MD
Giancarlo Attinà
Giuseppe Barbagallo, MD
Jason Barber, MS
Frederick Barker, MD
Lorenzo Bello, MD
Carolina Gesteira Benjamin, MD
Elizabeth Emily Bennett, MD, MS
David BergP
Mitchel S. Berger, MD
Mia Bertalan, BS
Chetan Bettegowda, MD, PhDP
Nikhilesh Bhatt
Orin Bolch, MD
George C. Bobustuc, MD
Courtney Bosse
Stephen G. Bowden, BM
Chris Bowman
Michael G. Brandel, BA
Daniel J. Brat
Priscilla Brastianos, MD
Christopher Alvarez-Breckenridge
Henry Brem, MD
John C. Breneman, MD
Andrew Brenner, MD
Philip Ryan Brinson, BS
George G. Bowden, BM
Michael G. Brandel, BA
Harley Brito da Silva, MD
Jeffrey N. Bruce, MD
Thomas Brucke
Peter D. Canoll, MD, PhD
Bob S. Carter, MD, PhD
Alessandra Casarotti
Dave Cavazos
Juanita Celix, MD
Francesco Certo, MD
Srikant S. Chakravarthi
Lola Blackwell Chambless, MD
Peter Chang, BA
Cleopatra Charalampaki, MD, PhD
Xiong-Hui Chen, MD
Andrew Chi, MD
Prashant Chittiboina, MD, MPH
Sarah Choi
Alvin Chou
Winward Choy, BA
Lawrence K. Chung, BS
Christopher P. Cifarelli, MD, PhD
Elizabeth Claus, MD
Lee Cooper
Martin Corsten, MD
Maura Cosetti
David J. Cote, BS
Honggang Cui
Michael Cusimano, MD
Randy D’Amico, MD
David J. Daniels, MD, PhD
John Dankert
Sunit Das, MD, PhD
Hormuzdiyar H. Dasenbrock, MD
Justin M. David, PhD
Tristan de Mooij, MD
J. Matthew Debnam, MD
John Degroot
Christopher P. Deibert
Jingjing Deng
Antonio DeSalles, MD, PhD
Michael C. Dewan, MD
Joseph D. DiDomenico, BS
Jorg Dietrich, MD, PhD
Francesco DiMeco, MD
Ninh Doan, MD, PhD
Xuezhi Dong, BA
Deborah L. Donohoe, BS
Heloise H. Dubois
Hugues Duffau, MD, PhD
Ian F. Dunn, MD
Nancy A. Edwards, BA
Christopher Farrell
Amir Fathi
Peter Fecci, MD, PhD
Manuel Ferreira, Jr.
Patirick Michael Flanigan, BS
John Robert Floyd, MD
Joshua Frenster
Melanie Fukui, MD
Gregory N. Fuller, MD, PhD
Sara Ganaha, MD
Marco Garavaglia
Sarah Tamara Garber, MD
Michael Garcia
Corey Gill, BS
Tomas Garzon-Muvdi, MD, MS
Zoran Gatalica
Abdi S. Ghodsi, MD
Brian John Andrew Gill
Steven L. Gogela, MD
Danielle Golub
Quinton Gopen, MD
Alessandra A. Gorgulho, MD
Yair M. Gozal, MD, PhD
Simon Graham, PhD
Jordan Green
Aleksandra Gruslova
Christine Guerrero
Hugo Guerrero Cazares, MD, PhD
Ghaith Habboub, MD
David Hackney
Sameer H. Halani, BA, MS
Xiaoxiao Han, MD
Yong Han
Mitsuto Hanihara, MD, PhD
Gregory Hare
Yuuri Hashimoto
Christina Hayes
Andrew Torre Healy, MD
Michele HeaphyP
Adriana Heguy
John D. Heiss, MD
Shawn L. Hervey-Jumper, MD
Stacy HilsabeckP
Brian R. Hirshman, MD, MS
Sze Chun Winson Ho, MD
Chad Holder
Yuan Hu, MD
Wei Hua
Judy Huang, MD
Xuan Hui, MD, ScM
Alhadi Igressa, MD
Rebecca Ihrie
Arman Jahangiri, BS
Robert Jenkins
Jonathan Jennings, MD
Aaron Johnson, PhD
Michael Kader
Piyush Kalakoti, MD
Steven N. Kalkanis, MDP
Tania B. Kaprealian
Aditya Vishwas Karhade, BE
Tomoyuki Kawataki, MD, PhD
Kartik Kasavabhotla
Kathleen KennedyP
Sammy Khalili, MD
Themasap Khan
Mustafa Khasraw
Wajin Jason Kim
Hiroyuki Kinouchi, MD, PhD
Santhi D. Konduri
Douglas Kondziolka, MD, MSc,
FRCS(C)
Jun Kong
Kristen Kozielski
Bryan Matthew Krueger, MD
Ruby Kuang, MS
Ravi Kumar, MD
John S. Kuo, MD, PhD, FACS
Svetlana Kvint, MD
Carlito Lagman, MD
Grace Y. Lai, MD, PhD
Jonathan B. Lamano, MS
Michael Lamba
Montserrat Aniul Lara-Velazquez
Sang Jin Lee
Michele LengermanP
Andre Levchenko
Tenzin Lhakhang
Bing Li
Gang Li
Jiang-an Li
Yanyan Li, MSc
Ran Lin
Mark E. Linskey, MD
Graham Lobel
Xiao-jie Lu, MD
Stephen T. Magill, MD, PhD
Asif Maknojia, MD
Sunil V. Manjila, MBBS
Sydney ManolaP
April MartinP
Ying Mao, MD
Dragan Maric
Juan Carlos Martinez-Gutierrez
Rory R. Mayer, MD
Roxanne Mayrand
David McCarthy
Ian E. McCutcheon, MD
Michael William McDermott, MD
Brian McGill, MS
Guy M. McKhann, MD
Jerry McLarty
Gautam U. Mehta, MD
Tom Mikkelsen, MD
Shama Mirza, PhD
Akshitkumar Mistry, MD
Aram Modrek
Alireza M. Mohammadi, MD
Ahmed Mohyeldin, MD
Annette Molinaro, MA, PhD
Andrew Montoura, MD
Melanie Morrison, BS
Wade M. Mueller, MD
Sean V. Murphy, PhD
Alona Muzikansky
Brian V. Nahed, MDP
Ichiro Nakano, MD, PhD
Michael Nalisnik
Anil Nanda, MD
Edjah K. Nduom, MD
Houtan Noushmehr
Justin A. Neira, BA
Thomas Neubert, PhD
Evan Newell
Ha Nguyen, MD
Christina Notarianni, MD
Goodwell Nzou, BS
Arnold Obungu
Jennifer Padwal, BS
Claudia Palena, PhD
Stefano Palmucci
Niko Papanikolaou
Sabrina Paratore
Deric M. Park
Ian F. Parney, MD, PhD
Vaibhav M. Patel, MD, BS
Luke E. Pater, MD
Panayiotis Emmanuel Pelargos,
BA
Federico Pessina
Timothy E. Peterson, MSc
Alexander Pomerantz
Jose Luis Porras
Nader Pouratian, MD, PhD
Alfredo Quinones-Hinojosa, MD
Valya Ramakrishnan
Aparna Rao, PhD
Sandeep Reddy
Angela Richardson, MD, PhD
Gabrielle E. Rieth, BS, MS
Marco Riva, MD
Cara Rogers
Xiaoming Rong, MD
Marco Rossi, MD
Robert C. Rostomily, MD
Richard A. Rovin, MD
James T. Rutka, MD, PhD,
FRCS(C), FACS
Navin C. Sabharwal
Jorge Samanamud
John H. Sampson, MD, PhD,
MHSc, MBA
Nader Sanai, MD
Jagteshwar Sandhu
Raymond E. Sawaya, MD
Lisa Scarpace
Paula Schiapparelli
Kathleen M. Schmainda, PhD
Alexander J. Schupper
Tom Schweizer, PhD
Michael Selch
Young-Joon Seol, PhD
Sagar R. Shah, MS
Mayur Sharma, MD, MCh
Sameer A. Sheth, MD, PhD
Regina ShupakP
Eric R. Siegel MSc
Danilo Silva, MD
Joshua Silverman, MD
Yannick Simmone
Gary R. Simonds, MD
Michael B. Sisti, MD
Saman Sizdahkhani
DeeDee Smart
Charlton Smith
Timothy R. Smith, MD, PhD, MPH
Matija Snuderl
Giuseppe Sortino
David Spetzler
Deanne StarrP
Glen Stevens, DO, PhD
David Straus, BA
Ryan Sullivan, MD
Ben Allen Strickland, MD
Timothy Struve, MD
Hao Su, PhD
Dima Suki, PhD
Nermin Sumru Bayin, MS
Fred Tam
Anita Tandle
Joseph E. Tanenbaum, BA
Stephen Tenn
John Thaman
Reid C. Thompson, MD
Nathaniel Tippens
Albert Truong
Aristotelis Tsirigos, PhD
Nolan Ung, BS
Timothy H. Ung, MD
Eugene John Vaios, MA
Jose Enrique Velazquez Vega
Roel Verhaak
Massimiliano Visocchi
Brittany Voth, BS
Sarika Walia, MD
Jing Wang
Qing Wang
Qingyue Wang, BS
Yujun Wang, PhD
Ronald E. Warnick, MD
Peter C. Warnke, MD
Shiao-Pei Weathers
Kyle D. Weaver, MD
Jeffrey S. Weinberg, MD
Christian Rainer-Wertz
Gabrielle A. White-Dzuro, MD
Elizabeth E. Wicks
Robert Thomas Wicks, MD
Amparo M. Wolf, MD, PhD
Eric Wolf, MS
Eric T. Wong, MD
Graeme Woodworth, MD
Xue-Shun Xie, BSc
Joanne Xiu
Sandra C. Yan, BS, BA
Isaac Yang, MD
Wuyang Yang, MD, MS
Stephen Yip, MD
James J. Yoo, MD, PhD
Jennifer Yu
Guoan Zhang
Pengcheng Zhang, PhD
Xiaoran Zhang, MD, MS
Shouhao Zhou, MD, PhD
You-Xin Zhou
Zhengping Zhuang
Disclosures
Nothing to Disclose

FLOSEAL Hemostatic Matrix Indication
FLOSEAL Matrix is indicated in surgical procedures (other than ophthalmic) as
an adjunct to hemostasis when control of bleeding by ligature or conventional
procedures is ineffective or impractical.
Important Risk Information for FLOSEAL Matrix
Do not inject or compress FLOSEAL Matrix into blood vessels. Do not apply FLOSEAL
Matrix in the absence of active blood flow, e.g., while the vessel is clamped or
bypassed, as extensive intravascular clotting and even death may result.
Do not use FLOSEAL Matrix in patients with known allergies to materials of bovine
origin. Do not use FLOSEAL Matrix in the closure of skin incisions because it may
interfere with the healing of the skin edges.
FLOSEAL Matrix contains Thrombin made from human plasma. It may carry a risk
of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-
Jakob disease (CJD) agent.
FLOSEAL Matrix is not intended as a substitute for meticulous surgical technique and
the proper application of ligatures or other conventional procedures for hemostasis.
Excess FLOSEAL Matrix (material not incorporated in the hemostatic clot) should
always be removed by gentle irrigation from the site of application.
FLOSEAL Matrix swells by approximately 10% to 20% after product is applied.
Maximum swell volume is achieved within about 10 minutes.
The safety and effectiveness of FLOSEAL Matrix has not been established in
children under 2 years of age and pregnant women.
Do not use air to remove residual FLOSEAL Matrix from Applicator tip. The
Applicator tips should not be cut. Do not use FLOSEAL Matrix on bone surfaces
where adhesives, such as methylmethacrylate or other acrylic adhesives, will be
required to attach a prosthetic device.
Rx Only. For safe and proper use of this device, refer to the full Instructions for Use.
Study design
Prospective, randomized, multi-center trial comparing FLOSEAL Matrix
with GELFOAM®
Hemostat+thrombin in stopping intraoperative
bleeding during spinal surgery. Four centers randomized 127 patients,
21 years of age or older. Randomization occurred after a bleeding
lesion requiring a topical hemostatic agent was identified. The primary
endpoint was hemostasis success for the first treated bleeding site. There
was no difference in the adverse event profile between the two groups.2
References: 1. FLOSEAL Hemostatic Matrix Instructions for Use. Hayward, CA: Baxter Healthcare
Corporation. 2. Renkens KL Jr, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized
trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26:1645-1650.
Baxter and Floseal are registered trademarks of Baxter International Inc.
Gelfoam is a registered trademark of Pharmacia Upjohn Company LLC,
and is used under license.
USMP/9/16-0019 07/2016
THE POWER OF FAST
ACHIEVES HEMOSTASIS TWICE AS FAST
AS GELFOAM®
HEMOSTAT + THROMBIN IN SPINE SURGERY1
(Median time to hemostasis: 1.5 minutes compared to 3.0 minutes)1,2
For more information or to place an order call 1-888-229-0001

DO YOU OWN THE MOMENT?
Visit us at booth 307
Gliadel® is manufactured by Eisai Inc. for Arbor Pharmaceuticals, LLC.
Gliadel® is a registered trademark of Eisai Inc ©2015 Arbor Pharmaceuticals, LLC.
PP-GLD-US-0049 All rights reserved.

Tumor Symposium

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (20)

Similar to Tumor Symposium

Similar to Tumor Symposium (20)

Tumor Symposium